FDA Approves Novel Preventive Treatment for Migraine

And since migraine with aura increases risk of stroke your doctor should be up-to-date on this intervention. They seem to have totally missed testing migraine with aura, that data point should have been included by the senior researcher.

Migraine with aura – but not without – increases risk of stroke  Sept. 2017

 

 Migraine Tied to Perioperative Stroke Risk 30-day ischemic stroke risk higher for those with migraine with aura  Jan. 2017 

 

Migraine with aura linked to clot-caused strokes March 2016 

The treatment here:

FDA Approves Novel Preventive Treatment for Migraine

ROCKVILLE, Md -- May 18, 2018 -- The US Food and Drug Administration (FDA) has approved erenumab-aooe (Aimovig) for the preventive treatment of migraine in adults.

The treatment is given by once-monthly self-injections. Erenumab-aooe is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.

“[Erenumab-aooe] provides patients with a novel option for reducing the number of days with migraine,” said Eric Bastings, MD, FDA’s Center for Drug Evaluation and Research, Rockville, Maryland. “We need new treatments for this painful and often debilitating condition.”

The effectiveness of erenumab-aooe for the preventive treatment of migraine was evaluated in 3 clinical trials. The first study included 955 participants with a history of episodic migraine and compared erenumab-aooe with placebo.

Over the course of s6 months, erenumab-aooe -treated patients experienced, on average, 1 to 2 fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared erenumab-aooe with placebo.

Over the course of 3 months, erenumab-aooe -treated patients experienced, on average, 1 fewer migraine days per month than those on placebo. The third study evaluated 667 patients with a history of chronic migraine and compared erenumab-aooe with placebo. In that study, over the course of 3 months, patients treated with erenumab-aooe experienced, on average, 2.5 fewer monthly migraine days than those receiving placebo.

The most common side effects that patients in the clinical trials reported were injection site reactions and constipation.

SOURCE: US Food and Drug Administration